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modifying anti-rheumatic drugs (DMARDs) or to both
DMARDs and anti-TNFs received the RA RTX regimen (1gx2).
The clinical outcome measure was moderate/good EULAR
response at 24 weeks. Responding patients were eligible to
re-treatment with RTX upon disease exacerbation after a
minimum of 48 weeks. Costs of RTX treatment (drug acquisition
& administration) were compared to average costs of the spared
anti-TNFs (inﬂiximab, etanercept or adalimumab) that would
have been provided otherwise to each patient until RTX
re-treatment or end of follow-up (FU). Prices are based on Israeli
tariff before VAT. RESULTS: A total of 108 patients were
enrolled. Sixty-seven DMARDs failures (62%), 41 DMARDs
and anti-TNF failures (38%). At time of analysis (January 2008),
89 patients completed a minimum of 24 weeks follow-up (FU).
Three dropped out in less than 24 weeks. Median FU: 75 weeks.
35/89 patients (39%) received re-treatment with RTX at a
median of 63 weeks. A total of 37/89 patients (42%) were (at
time of analysis) still on FU with no other treatment (median FU:
93wks). Average cost in Israel of anti-TNF treatment: NIS1955
(~560$)/week Cost of RTX (2g): NIS34,448 (~$9,840). The total
saving per patient (up to data cutoff) results in NIS85,258
(~$24,360). Overall cost saving during this period for 92 patients
was NIS7,844 million (~$2,241,120). This sum is still an under-
estimation since 42% of the patients still require no further
treatment, and continue to spare anti-TNF therapy. CONCLU-
SIONS: From the payer perspective, RTX treatment is a signiﬁ-
cant cost-saving alternative for patients with RA in the Israeli
public health care setting.
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OBJECTIVES: RA is a chronic disease associated with a signiﬁ-
cant use of health care resources, imposing a substantial eco-
nomic burden to patients, health insurance and to society in
France. The objective of the present study was to assess the use of
direct medical resources excluding drug costs by RA patients in
France and to derive original costing data per level of disease
activity. METHODS: An advanced standard costing approach
was performed in collaboration with a panel of expert clinicians
highly experienced in the management of RA in France. Four
categories of disease activity were deﬁned according to DAS28
thresholds: patients (pts) achieving remission (DAS <2.6), pts not
achieving remission (DAS 2.6), pts achieving low disease activ-
ity state (LDAS; DAS 3.2) and pts not achieving LDAS (DAS
>3.2). Eight resource utilization items were deﬁned: medical
visits, laboratory tests, hospitalization, imaging, physiotherapy,
nursing, adaptive aids and transportation. Resource utilization
and unit costs from the national payer perspective were collected
and simulated using distribution ranges for each item. Using a
simulation model, a computation of all costs distributions was
performed to estimate the overall costs per six months over a
2-year time horizon. RESULTS: Direct medical costs were esti-
mated per disease activity level. For pts achieving remission
during the ﬁrst 6 months, about 90% generated costs under
€1000, with costs estimated at €771 (SD = 199) per 6 months
and €511 (SD = 162) for each subsequent 6 months (p < 0.001).
For pts not achieving remission per 6 months, about 85% gen-
erated costs under €1500, with costs estimated at €1159 per 6
months (SD = 339). For pts achieving LDAS, costs were esti-
mated at €905 (SD = 263) per 6 months and €696 (SD = 240) for
each subsequent 6 months (p < 0.001). For pts not achieving
LDAS, costs were estimated at €1215 per 6 months (SD = 405).
Key costs drivers were medical visits, laboratory tests and trans-
portation. CONCLUSIONS: This cost of illness assessment pro-
vides precise and current estimates of medical direct costs per RA
disease activity in France, conﬁrming that RA imposes a substan-
tial economic burden. The ﬁndings suggest that achieving LDAS
or remission is associated with substantially lower RA medical
costs.
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OBJECTIVES: To estimate the cost savings in outpatient
medical resource use associated with diagnosing ﬁbromyalgia
during the four years after ﬁbromyalgia diagnosis. METHODS:
A questionnaire was created based on the medical resources use
from 2260 patients diagnosed with FM between January 1998
and March 2003 in the General Practice Research Database
(FF-GPRD) in United-Kingdom. Local experts were asked to
compare their own clinical practice to UK prescriptions and
resource use, over a period of four years before diagnosis to four
plus years after diagnosis using one year cross-sections. Poisson
loglinear regression models, published for the UK, allowed to
estimate the medical resources consumed if no diagnosis had
been established. The impact of diagnosis was evaluated for each
of these medical resources. Costs were calculated by multiplying
resource use with corresponding Spanish unit costs (€; 2008;
both public health care payer perspective and societal perspec-
tive including patient co-payments). RESULTS: This study con-
ﬁrms previously published results obtained for the UK and
France: whereas costs gradually increase before diagnosis, a
stagnation in costs increase occurs in the year after diagnosis,
subsequently followed by a moderate decrease afterwards. The
savings made as a result of ﬁbromyalgia diagnosis add up to
€421 per patient and per year from the health care system per-
spective and €432 from a societal point of view. Diagnostic tests,
referrals to specialists, GP visits and drugs represent respectively
42%, 29%, 15% and 14% of these savings, CONCLUSIONS:
Compared to a diagnosed ﬁbromyalgia patient, a not diagnosed
patient in Spain represents an incremental cost of €421 from the
health care payer perspective.
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OBJECTIVES: To estimate the costs savings in outpatient
medical resource use associated with diagnosing ﬁbromyalgia
during the four years after ﬁbromyalgia diagnosis, METHODS:
A French expert panel, involving 33 general practitioners (GPs)
and 27 rheumatologists, was questioned in 2007 by means of a
questionnaire describing the UK prescriptions registered in the
General Practice Research Database between January 1998 and
March 2003 (2260 ﬁbromyalgia patients). Participating experts
were asked to describe their clinical practice compared to the UK
prescriptions in terms of diagnostic tests, drugs, consultations
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and referrals. over a period of 4 years before diagnosis to
4 years—plus after diagnosis using one year intervals. Poisson
loglinear regression models, published for the UK, allowed to
estimate the medical resources consumed if no diagnosis had
been established. The impact of diagnosis was evaluated for each
of these medical resources. Costs were calculated by multiplying
resource use with corresponding French unit costs (€; 2007; both
public health care payer perspective and societal perspective
including patient co-payments). RESULTS: This study conﬁrms
previously published results for the UK: whereas costs gradually
increase before diagnosis, a stagnation in costs increase occurs in
the year after diagnosis, subsequently followed by a moderate
decrease afterwards. The same trend was observed whether the
panel consisted of GP or rheumatologists. The savings made as a
result of ﬁbromyalgia diagnosis add up to €126 per patient and
per year in France from the health care system perspective and
€184 from a societal perspective. GP visits, diagnostic tests, drugs
and referrals to specialists represent respectively 57%, 23%,
12% and 8% of these savings. CONCLUSIONS: Compared to a
diagnosed ﬁbromyalgia patient, a not diagnosed patient repre-
sents an incremental cost of €126 from the public health care
payer perspective, mainly due to medical nomadism and multi-
plication of investigations and prescriptions.
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OBJECTIVES: Osteoarthritis is a common chronic illness affect-
ing 20 million persons in the United States. To date, however,
there is very little evidence quantifying the effects of osteoarthri-
tis on the cost of job absenteeism and presenteeism. Yet such
information would be useful to employers in designing health
beneﬁts for their employees. METHODS: Using data from the
Medical Expenditure Panel Survey (MEPS), a large nationally-
representative database from the United States, this study per-
forms bivariate and multivariate analyses to quantify the
relationship between osteoarthritis and annual job absenteeism
costs to employers. Individual estimates by occupation, as well
as nationally-aggregated measures, will be provided. RESULTS:
We ﬁnd that osteoarthritis signiﬁcantly increases job absenteeism
by 2.39 days per annum (p < 0.01), raising job absenteeism costs
by $478 per employee. These differences vary by occupation,
and are largest for workers in the service sector ($1070), ofﬁce
workers ($922) and equipment operators ($1084). Subjects
working in managerial, sales, and professional occupations miss
on average half as many days of work from osteoarthritis than
do subjects in traditionally blue-collar occupations. Job absen-
teeism costs from osteoarthritis are larger for females ($554)
than for males ($342). CONCLUSIONS: These results indicate
that job absenteeism due to osteoarthritis is pervasive and are an
inherent cost in the work place. Employers may realize substan-
tial productivity gains in their workers by promoting alternative
treatment regimens to mitigate the debilitating effects of this
disease.
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OBJECTIVES: Osteoarthritis is a major debilitating disease
afﬂicting approximately 20 million persons in the United States.
Yet, the ﬁnancial and societal costs to patients, insurers, and
society from osteoarthritis remains poorly understood.
METHODS: Using data from the Medical Expenditure Panel
Survey (MEPS) a large, nationally-representative database from
the United States, this study performs bivariate and multivariate
analyses to quantify the relationships between osteoarthritis and
annual health care costs to patients, insurers, and society. Indi-
vidual and nationally-aggregated cost estimates will be provided.
RESULTS: Overall annual health care costs are dramatically
higher in subjects with a diagnosis of osteoarthritis than in sub-
jects without osteoarthritis ($10,803 vs $3,427, p < 0.01). This
cost differential is particularly great among African-Americans
with osteoarthritis compared to African Americans without
osteoarthritis ($13,937 vs $3,293, p < 0.01)). This reﬂects the
high prevalence of osteoarthritis among Africa-Americans. The
total cost of osteoarthritis is dramatically and signiﬁcantly lower
(p < 0.01) among uninsured subjects ($2,875) than among sub-
jects with private insurance ($11,798) or private ($11,093) insur-
ance. This suggests that uninsured subjects with osteoarthritis are
facing serious health care access problems. Large differences in
total costs from osteoarthritis persist when the sample is strati-
ﬁed by age, gender, educational attainment, insurance status,
weight classiﬁcation, and geographic location. Out-of-pocket
health care costs are much higher among subjects with osteoar-
thritis ($1757 vs. $649, p < 0.01) and are also higher for insurers
($9047 vs. $2279, p < 0.01). CONCLUSIONS: These ﬁndings
indicate that the cost burden from osteoarthritis is quite large for
all groups and falls disproportionately on African-Americans and
uninsured individuals.
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OBJECTIVES: To estimate the medical and non-medical
resources use and related costs from the health insurance and
societal perspective, in the management of ﬁbromyalgia patients
in Spain, METHODS: A questionnaire was created based on the
resources use from 2260 ﬁbromyalgia patients extracted from the
General Practice Research Database in United-Kingdom. Local
experts were asked to compare their own clinical practice to UK
prescriptions and resource use, over a period of four years before
diagnosis to four years plus years after diagnosis. Prescription
data related to paramedical and alternative care were also col-
lected. Costs were calculated by multiplying prescribed resource
use with corresponding Spanish unit costs (€; 2007; both public
health care payer perspective and societal perspective including
patient co-payments). Inpatient care and productivity loss were
not considered. RESULTS: The mean medical treatment cost
represents €536 per patient per year from the health care payer
perspective (i.e. 74% visits cost, 14% drugs cost, and 12%
diagnostic tests cost) and €549 from the societal perspective. If
paramedical and alternative treatments are included, the esti-
mated cost of ﬁbromyalgia is €674 per patient per year from a
societal perspective and €536 from a health care payer perspec-
tive. The costs of paramedical and alternative treatments repre-
sent 18.5% of the total costs (of which 73% paramedical acts,
23% alternative treatment and 4% food supplements). The
annual patient co-payment is estimated at 138 euros. CONCLU-
SIONS: In Spain, the cost of outpatient management of ﬁbromy-
algia is estimated at €674 per patient per year from a societal
perspective and at €536 from the public health care payer
perspective.
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